While most of the patients treated with PI3K or mTOR inhibitors in these trials had PD, some patients experienced disease control, highlighting the need for further investigation into the PI3K/AKT/mTOR pathway in treating ACC. This evidence concerns the gene MTOR and adrenal cortex carcinoma.